



Coherus BioSciences to Highlight New Product Pipeline, Cancer Immunotherapy Development Plans at March 29, 2022 Analyst Day Event

REDWOOD CITY, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), today announced that Coherus plans to host an Analyst Day on March 29, 2022 at 9:30 a.m. ET in New York City. Coherus executives and scientists will provide updates on the preparation for multiple potential new product launches anticipated over the next 15 months as well as the Company's transformational entry into immuno-oncology with PD-1 inhibitor toripalimab and innovative PD-1 combination candidates.

Investors and analysts who would like to attend the Coherus Analyst Day event in-person or virtually may pre-register [here](#).

A live webcast of the Analyst Day will be available on the [Events & Presentations](#) page of the Coherus website at <https://investors.coherus.com>. Please access the website prior to the start of the event to ensure a timely connection to the webcast. A replay of the event will be archived on the Coherus website for 30 days.

About Coherus BioSciences

Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus' strategy is to build a leading immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics.

In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody, for the United States and Canada. A BLA for toripalimab for the treatment of metastatic or recurrent nasopharyngeal carcinoma is currently under priority review by the FDA, with a target action date of April 30, 2022. Toripalimab is also being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder.

Coherus markets UDENYCA[®] (pegfilgrastim-cbqv), a biosimilar of Neulasta[®] in the United States, and expects to launch the FDA-approved Humira[®] biosimilar YUSIMRY[™] (adalimumab-aqvh) in the United States in 2023. The FDA is currently reviewing the BLA for CIMERLI[™], formerly known as CHS-201, a biosimilar of Lucentis[®] (ranibizumab), with a target action date of August 2022. Coherus is also developing CHS-305, a biosimilar of Avastin[®] (bevacizumab).

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Coherus' ability to build its immuno-oncology franchise to achieve a leading market position; Coherus' ability to generate cash; Coherus' investment plans; Coherus' expectations for its timing and ability to launch new products; and expectations for the advancement of PD-1 combination candidates.

Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus' actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; risks relating to the COVID-19 pandemic; risks related to our existing and potential collaboration partners; risks of the drug development position of Coherus' competitors; the risks and uncertainties of the regulatory approval process, including the speed of regulatory review and the timing of Coherus' regulatory filings; the risk of FDA review issues; the risk of Coherus' execution of its change in strategy from a focus on biosimilars to a strategy using cash from its portfolio of FDA-approved therapeutics to fund an immuno-oncology franchise; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus' drug candidates; and the risks and uncertainties of possible litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus' business in general, see Coherus' Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on February 23, 2022, including the section therein captioned "Risk Factors" and in other documents we file with the Securities and Exchange Commission.

UDENYCA[®], YUSIMRY[™] and CIMERLI[™], whether or not appearing in large print or with the trademark symbol, are trademarks of Coherus, its affiliates, related companies or its licensors or joint venture partners, unless otherwise noted. Trademarks and trade names of other companies appearing in this Press Release are, to the knowledge of Coherus, the property of their respective owners.

Coherus Contact Information

Investors:

McDavid Stilwell
Chief Financial Officer
Coherus BioSciences, Inc.
IR@coherus.com

Media:

Kelli Perkins
Red House
kelli@redhousecomms.com



Source: Coherus BioSciences, Inc.